The Lancet

The Lancet

@thelancet · Twitter ·

Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). A new trial investigated the addition of neoadjuvant, concurrent, and adjuvant atezolizumab with SBRT: https://spkl.io/60127uhzK

Research in context panel for a paper published in The Lancet entitled \"Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914):\na multicentre, open-label, superiority, phase 3, randomised controlled trial. Copyright: 2026 Elsevier Ltd. All rights reserved.